Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOSTON: Selinexor, Bortezomib, and Dexamethasone in RRMM
NCT03110562Phase 3Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- May 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of selinexor in multiple myeloma (MM), sponsored by Karyopharm Therapeutics Inc.. Started May 2017; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03110562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110562.